Table of Contents
- Trial overview
- Who can join
- What is being measured
- Treatment groups in the study
- Study design and phase
- Why this trial matters for patients
Trial overview
The clinical trial with ID NCT07169851 is studying LY3537021 for nausea and vomiting caused by chemotherapy in adults with cancer.[1] The study is authorised and is planned as a Phase 2 interventional trial.[1] It plans to enroll 205 people.[1]
Who can join
This trial is for adults with cancer who are receiving chemotherapy and have nausea and vomiting related to that treatment.[1] The source data does not list more detailed entry rules, so final participation depends on the study team’s screening checks.[1]
What is being measured
The main outcome is complete response in the delayed phase of chemotherapy-induced nausea and vomiting.[1] In this study, complete response means no vomiting and no rescue medication.[1] Rescue medication is extra medicine used if symptoms are not fully controlled.[1]
Treatment groups in the study
The study compares LY3537021 plus other anti-nausea treatments with placebo plus the same background anti-nausea treatments.[1] The listed background medicines include ondansetron, aprepitant, palonosetron, granisetron, dexamethasone, and 0.9% sodium chloride.[1] A placebo is a look-alike treatment used for comparison that does not contain the study drug.[1]
Study design and phase
This is an interventional study, which means researchers give a treatment and then measure the results.[1] It is a Phase 2 trial, which usually looks at early signs of how well a treatment works and continues to check safety.[1] The trial is focused on patients with cancer who need help preventing or reducing chemotherapy-related nausea and vomiting.[1]
Why this trial matters for patients
Chemotherapy-related nausea and vomiting can make cancer treatment harder to tolerate, so studies like this try to find better ways to control symptoms.[1] The delayed phase is important because symptoms can continue after treatment ends, not just right away.[1] By measuring complete response, researchers can see whether LY3537021 helps patients avoid vomiting and avoid needing extra medicine.[1]
